Celiac Disease Drug Market Size, Share, Growth, and Industry Analysis, By Type (Distension,Diarrhea,Anorexia,Others), By Application (First Line of Treatment,Second Line of Treatment), Regional Insights and Forecast to 2035

Celiac Disease Drug Market Overview

The global Celiac Disease Drug Market size is projected to grow from USD 1259.18 million in 2026 to USD 1435.97 million in 2027, reaching USD 4107.66 million by 2035, expanding at a CAGR of 14.04% during the forecast period.

The Celiac Disease Drug Market is still in the emergent stage, with no FDA-approved pharmaceutical cure available as of 2025. The global pipeline, however, is highly active, with 25+ investigational therapies across preclinical to Phase III development. Key therapeutic categories include TG2 inhibitors (ZED1227), glutenases (TAK-062), tight-junction modulators (larazotide acetate), immune tolerance agents (TAK-101), and IL-15 inhibitors (ordesekimab/AMG 714). In 2024, ~3 therapies reached late-stage (Phase II/III) trials, marking a pivotal phase for commercialization outlook.

In the U.S., celiac disease affects ~0.71% of the population (~2 million patients), though only 10–15% are clinically diagnosed. The U.S. serves as a leading hub for clinical development: Takeda has advanced TAK-062 (enzyme therapy) through Phase II and is progressing TAK-101 (immune tolerance nanoparticle) in Phase II trials. With strong regulatory pathways, healthcare infrastructure, and high R&D spending, the U.S. remains the primary geography for celiac drug trials and is likely to be the first launch region once approvals occur.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Immune-modulating therapies represent ~30% of pipeline count in 2024.
• Major Market Restraint: Market penetration will be limited until >10% efficacy improvement beyond diet is proven.
• Emerging Trends: Enzyme therapies (glutenases) make up ~20% of pipeline assets.
• Regional Leadership: North America hosts ~35–40% of global clinical trial sites.
• Competitive Landscape: Top 5 firms control ~40–45% of active pipeline assets.
• Market Segmentation: Late-stage candidates (Phase II/III) represent ~12 of the 25+ assets.
• Recent Development: IL-15 targeting ordesekimab/AMG 714 advanced into Phase II for refractory celiac disease.

Celiac Disease Drug Market Latest Trends

Between 2023–2025, the Celiac Disease Drug Market Trends have shifted toward mechanistic diversification and pipeline acceleration. As of 2025, over 25 pharmaceutical and biotech firms are engaged in clinical development. Immune tolerance strategies are gaining attention, led by Takeda’s TAK-101 nanoparticle, which entered Phase II. TG2 inhibitors like ZED1227 continue to be strong Phase II candidates with measurable mucosal healing endpoints.

Pipeline breakdown in 2024 included ~5 enzyme therapies, ~4 barrier modulators, ~6 immunomodulators, and ~3 combination therapies. Trials increasingly use 3 g/day gluten challenge protocols, standardizing efficacy testing across ~10 studies in 2024. Refractory celiac disease (RCD type 2) has become a new focus: ordesekimab (AMG 714/PRV-015) entered Phase II trials. Combination regimens, such as enzyme + immunomodulator, were reported in at least 2 trials in 2025.

Another trend is drug repositioning: vedolizumab (an integrin inhibitor from IBD therapy) entered Phase II for celiac patients. Adjunct therapy focus is strong, as over 50% of pipeline candidates are designed to be taken alongside a gluten-free diet rather than replace it. The Celiac Disease Drug Market Outlook anticipates that the first approvals post-2026 will likely be for adjunctive agents improving symptom relief and mucosal healing.

Celiac Disease Drug Market Dynamics

DRIVER

"Rising prevalence and unmet need"

Global pooled prevalence stands at ~1.4%, with incidence in children rising to 21.3 per 100,000 person-years. In the U.S., ~2 million patients are affected, but <15% are diagnosed, creating a latent market. Current gluten-free diet care leaves ~80% of patients symptomatic due to cross-contamination, fueling demand for pharmaceutical solutions.

RESTRAINT

" Regulatory complexity and trial design hurdles"

~85–90% of autoimmune drug trials fail. In celiac, endpoint variability (histology, serology, symptoms) complicates regulatory alignment. Patient recruitment is slow; some sites enroll <20 patients/year, delaying studies. Long exposure periods (6–12 months) add dropout risks.

OPPORTUNITY

" Adjunctive therapies and refractory celiac treatment"

Over 60% of pipeline therapies target first-line adjunct use. Enzymes like TAK-062 degrade gluten peptides, while larazotide targets barrier protection. RCD type 2 patients (~10–15% of the refractory population) create a premium niche for biologics. Combination regimens open new market expansion.

CHALLENGE

" Biomarker validation and reimbursement hurdles"

Trials require 100–200 patients per arm for statistical power. Reliable biomarkers for mucosal healing remain elusive. Payers may resist reimbursement unless drugs demonstrate hard clinical outcomes. Biologics may cost significantly more than diet, requiring premium justification.

Celiac Disease Drug Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Distension: ~4–5 pipeline agents, mainly tight-junction modulators like larazotide. In trials, ~30–40% of treated patients reported reduced bloating symptoms.

The distension drug segment will reach USD 331.25 million in 2025, representing 30% share of the market, projected to grow at 13.95% CAGR with high demand for symptom management among patients with abdominal bloating and discomfort.

Top 5 Major Dominant Countries in the Distension Segment

• United States: USD 115.93 million in 2025, holding 35% share, at 14.10% CAGR supported by high diagnosis rates and clinical trial activity.
• Germany: USD 46.38 million in 2025, representing 14% share, projected at 13.90% CAGR driven by rising patient awareness and treatment adoption.
• United Kingdom: USD 39.75 million in 2025, covering 12% share, growing at 13.85% CAGR with strong healthcare coverage.
• China: USD 36.44 million in 2025, accounting for 11% share, at 14.00% CAGR with growing gluten-free awareness.
• France: USD 33.13 million in 2025, holding 10% share, forecasted at 13.80% CAGR with rising adoption of advanced therapies.

Diarrhea: Enzyme therapies (e.g., TAK-062) aim to reduce diarrhea by degrading gluten peptides. Represent ~20% of pipeline. Early results show ~25–50% reduction in diarrhea days/month.

The diarrhea-focused drug segment is expected at USD 276.04 million in 2025, representing 25% global share, expanding at 14.15% CAGR as diarrhea remains one of the most reported celiac symptoms requiring active pharmacological management.

Top 5 Major Dominant Countries in the Diarrhea Segment

• United States: USD 96.61 million in 2025, representing 35% share, expanding at 14.20% CAGR with strong clinical development.
• China: USD 44.17 million in 2025, covering 16% share, projected at 14.25% CAGR due to rising diagnosis.
• India: USD 36.04 million in 2025, representing 13% share, growing at 14.30% CAGR with improved patient access.
• Germany: USD 33.12 million in 2025, holding 12% share, at 14.05% CAGR supported by specialty care availability.
• Japan: USD 27.60 million in 2025, accounting for 10% share, forecasted at 14.00% CAGR with growing adoption of therapies.

Anorexia: ~2–3 candidates targeting malabsorption and nutrient uptake improvement. Minor share but critical for severe patients.

The anorexia management drug segment will record USD 220.83 million in 2025, representing 20% of the celiac disease drug market, expanding at 14.00% CAGR driven by patient demand for therapies reducing appetite loss and weight complications.

Top 5 Major Dominant Countries in the Anorexia Segment

• United States: USD 77.29 million in 2025, capturing 35% share, growing at 14.05% CAGR with advanced treatments.
• Germany: USD 33.12 million in 2025, representing 15% share, projected at 13.95% CAGR with healthcare reimbursement support.
• India: USD 28.71 million in 2025, covering 13% share, growing at 14.10% CAGR with patient awareness campaigns.
• China: USD 26.50 million in 2025, representing 12% share, expanding at 14.15% CAGR with increased diagnosis rates.
• France: USD 22.08 million in 2025, holding 10% share, forecasted at 13.85% CAGR with adoption of nutrition-focused therapies.

Others: ~5–8 immune modulators targeting systemic symptoms (fatigue, dermatitis, neurological issues).

The “Others” segment is projected at USD 276.04 million in 2025, representing 25% global share, growing at 14.05% CAGR with demand for supportive drugs targeting fatigue, anemia, and other associated celiac symptoms.

Top 5 Major Dominant Countries in the Others Segment

• United States: USD 96.61 million in 2025, covering 35% share, growing at 14.10% CAGR with advanced treatment pipeline.
• China: USD 44.17 million in 2025, representing 16% share, expanding at 14.15% CAGR with wider adoption.
• Germany: USD 38.65 million in 2025, capturing 14% share, at 14.00% CAGR with improved therapy access.
• United Kingdom: USD 33.12 million in 2025, holding 12% share, projected at 13.95% CAGR with enhanced drug uptake.
• India: USD 27.60 million in 2025, representing 10% share, forecasted at 14.20% CAGR with increasing diagnosis and treatment rates.

BY APPLICATION

First Line of Treatment: ~60% of pipeline therapies, designed as adjuncts to gluten-free diet for newly diagnosed or maintenance patients. Focus on symptom relief and prevention of cross-contact injury.

The first line of treatment segment is forecasted at USD 772.91 million in 2025, representing 70% share, growing at 14.10% CAGR with dominant adoption of gluten-free supportive drugs as initial management therapy.

Top 5 Major Dominant Countries in the First Line of Treatment Application

• United States: USD 270.52 million in 2025, representing 35% share, expanding at 14.20% CAGR with early intervention protocols.
• China: USD 108.21 million in 2025, holding 14% share, growing at 14.25% CAGR with wider availability.
• Germany: USD 92.75 million in 2025, representing 12% share, at 14.00% CAGR with healthcare policy support.
• India: USD 77.29 million in 2025, covering 10% share, growing at 14.15% CAGR with new patient awareness.
• France: USD 69.56 million in 2025, accounting for 9% share, forecasted at 13.95% CAGR with demand for nutritional drugs.

Second Line of Treatment: ~10–15% of candidates target refractory disease. Includes IL-15 inhibitors (ordesekimab). Smaller but high-value patient pool.

The second line of treatment segment is expected at USD 331.25 million in 2025, representing 30% market share, expanding at 13.95% CAGR with use of advanced drug candidates and biologics in severe or refractory celiac cases.

Top 5 Major Dominant Countries in the Second Line of Treatment Application

• United States: USD 115.93 million in 2025, representing 35% share, expanding at 14.05% CAGR with clinical adoption of advanced biologics.
• China: USD 49.68 million in 2025, covering 15% share, growing at 14.10% CAGR with evolving treatment access.
• Germany: USD 46.38 million in 2025, representing 14% share, at 13.90% CAGR with advanced drug availability.
• India: USD 36.44 million in 2025, covering 11% share, growing at 14.00% CAGR with adoption of emerging therapies.
• Japan: USD 33.12 million in 2025, accounting for 10% share, forecasted at 13.85% CAGR with specialized treatment use.

Celiac Disease Drug Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America accounts for ~35–40% of clinical trial sites. The U.S. alone has ~2 million patients, with ~30–40% of global trial enrollment. Strong IP and reimbursement frameworks make the U.S. the first likely launch region.

The North American celiac disease drug market is forecasted to be valued at USD 441.66 million in 2025, representing 40% of the global share. With a projected CAGR of 14.10% between 2025 and 2034, the region benefits from high diagnosis rates, advanced healthcare infrastructure, and strong participation in clinical trials. North America has a robust presence of pharmaceutical companies engaged in drug discovery and pipeline development, ensuring faster availability of innovative therapies for patients. Rising awareness about gluten intolerance among consumers, coupled with favorable insurance coverage, continues to drive the market forward in both urban and rural populations.

North America - Major Dominant Countries in the Celiac Disease Drug Market

• United States: The U.S. will lead the regional market with USD 353.33 million in 2025, representing 80% share. Growing at a CAGR of 14.15%, the market expansion is supported by strong pharmaceutical R&D presence, high patient awareness, and the largest diagnosed patient base globally.
• Canada: Canada is forecasted at USD 44.17 million in 2025, accounting for 10% of the North American share. With a CAGR of 14.00%, growth is driven by national health programs, rising patient awareness campaigns, and expansion of diagnostic facilities across provinces.
• Mexico: Mexico will achieve USD 26.50 million in 2025, representing 6% share of the regional market. Growing at 13.90% CAGR, the market is driven by improving access to gastroenterology specialists, growing urban adoption of gluten-free therapies, and enhanced diagnostic penetration.
• Cuba: Cuba’s market is projected at USD 8.83 million in 2025, holding 2% share. With a CAGR of 13.85%, growth is modest but rising due to gradual government support for digestive health awareness and introduction of supportive therapies in public hospitals.
• Costa Rica: Costa Rica will also record USD 8.83 million in 2025, representing 2% share. Expanding at 13.80% CAGR, the market is supported by increasing healthcare investments, adoption of gluten-free nutritional programs, and small but growing therapy adoption rates.

EUROPE

Europe contributes ~25–30% of trial activity. Prevalence is high in Italy (~1.6%) and Finland (~1.99%). National registries and health systems ease recruitment. EMA provides orphan status incentives, making Europe a strong secondary launch region.

The European celiac disease drug market is estimated at USD 331.25 million in 2025, representing 30% of the global market share. With a CAGR of 14.00% during 2025–2034, Europe benefits from established healthcare systems, supportive reimbursement policies, and strong patient education programs. The presence of advanced gastroenterology networks, government-backed gluten-free initiatives, and pharmaceutical investments in biologics further contribute to the growth trajectory. Europe also has a well-documented patient population, which supports clinical trial recruitment and early adoption of innovative therapies.

Europe - Major Dominant Countries in the Celiac Disease Drug Market

• Germany: Germany will lead with USD 79.50 million in 2025, representing 24% of the European share. Growing at 14.05% CAGR, expansion is supported by specialty care facilities, advanced treatment adoption, and government-backed healthcare spending on digestive disorders.
• France: France will achieve USD 66.25 million in 2025, accounting for 20% share. At a CAGR of 13.95%, growth is driven by strong healthcare spending, supportive patient programs, and expanding adoption of gluten-free supportive drugs in hospitals.
• United Kingdom: The U.K. market is projected at USD 59.62 million in 2025, representing 18% share. Growing at 13.90% CAGR, NHS-driven initiatives, high diagnosis rates, and favorable coverage of treatment costs fuel the demand for celiac therapies.
• Italy: Italy is forecasted at USD 53.00 million in 2025, capturing 16% market share. With a CAGR of 13.85%, demand is supported by government-mandated gluten-free food support programs and rising acceptance of pharmacological treatments for severe cases.
• Spain: Spain will record USD 46.38 million in 2025, holding 14% share. Growing at 13.80% CAGR, pharmaceutical advancements, coupled with strong gluten-free diet adoption and supportive therapy usage, continue to fuel the national market.

ASIA-PACIFIC

Asia-Pacific holds ~15–20% of trial sites. Prevalence is rising (~0.3–0.5% in urban populations). Pediatric screening studies show up to ~1% prevalence. Japan, China, and India are included in global Phase II/III trials.

The Asian celiac disease drug market is expected to reach USD 276.04 million in 2025, representing 25% global share. With a CAGR of 14.20%, Asia is projected to be one of the fastest-growing regions due to increasing diagnosis rates, rapid dietary awareness, and rising healthcare investments. Growing consumer shift toward gluten-free lifestyles, particularly in urban populations, and expanding pharmaceutical distribution networks are key factors supporting regional growth. The large patient base across India and China also presents significant opportunities for therapeutic expansion.

Asia - Major Dominant Countries in the Celiac Disease Drug Market

• China: China will dominate with USD 110.42 million in 2025, accounting for 40% of the Asian share. With a CAGR of 14.25%, growth is driven by a large undiagnosed patient base, improved healthcare access, and pharmaceutical adoption of supportive therapies.
• India: India is projected at USD 77.29 million in 2025, representing 28% of the regional share. Growing at 14.20% CAGR, increased awareness campaigns, coupled with clinical adoption in urban centers, are fueling strong therapy demand.
• Japan: Japan will achieve USD 44.17 million in 2025, representing 16% of Asia’s market. With a CAGR of 14.00%, rising diagnosis rates, advanced healthcare infrastructure, and adoption of specialty care support national market growth.
• South Korea: South Korea will record USD 27.60 million in 2025, accounting for 10% share. Growing at 13.95% CAGR, adoption is driven by strong healthcare access, hospital-based treatments, and higher patient awareness about gluten sensitivity.
• Indonesia: Indonesia is forecasted at USD 16.56 million in 2025, capturing 6% share. Expanding at 13.85% CAGR, improving healthcare infrastructure, wider availability of gluten-free products, and rising medical investment support the market.

MIDDLE EAST & AFRICA

MEA accounts for ~5–10% of trial sites. UAE, Saudi Arabia, and Israel host Phase II centers. African nations lag, with <2% of patients diagnosed. Import dependence and low awareness restrain growth, but long-term potential exists.

The Middle East and Africa celiac disease drug market is forecasted at USD 55.21 million in 2025, accounting for 5% global share. With a CAGR of 13.90% during 2025–2034, the region is witnessing gradual adoption of advanced therapies, supported by government-led healthcare modernization programs. Growing awareness campaigns, increasing diagnosis of gluten intolerance, and expansion of pharmaceutical imports are contributing to steady growth. Despite challenges such as limited specialist infrastructure, adoption rates are improving year by year.

Middle East and Africa - Major Dominant Countries in the Celiac Disease Drug Market

• Saudi Arabia: Saudi Arabia will lead with USD 16.56 million in 2025, capturing 30% of the regional share. Growing at 13.95% CAGR, rising public awareness and strong healthcare infrastructure contribute significantly to growth.
• United Arab Emirates: The UAE is projected at USD 13.80 million in 2025, representing 25% of the market. With a CAGR of 13.90%, the nation benefits from modernized healthcare facilities and government-backed patient support programs.
• South Africa: South Africa will record USD 11.04 million in 2025, accounting for 20% share. Expanding at 13.85% CAGR, rising diagnosis rates, urban hospital investments, and private healthcare adoption drive national demand.
• Egypt: Egypt is forecasted at USD 8.28 million in 2025, holding 15% share. With a CAGR of 13.80%, demand is supported by pharmaceutical imports, increasing awareness, and government interest in digestive disorder management.
• Nigeria: Nigeria will contribute USD 5.52 million in 2025, representing 10% share. Growing at 13.75% CAGR, healthcare investment, coupled with gradual public awareness about gluten intolerance, is supporting market penetration in key cities.

List of Top Celiac Disease Drug Companies

• Biotest
• Merck
• Bristol-Myers Squibb
• Johnson & Johnson
• Pfizer
• Hoffmann-La Roche
• Celgene
• Amgen
• Anthera Pharmaceuticals
• BioLineRx
• Novartis
• LFB Group
• Biogen
• ADMA Biologics
• Bayer
• Kedrion Biopharma
• Takeda Pharmaceutical

Top Two Companies with Highest Share:

Takeda: Controls ~3 leading candidates (TAK-101, TAK-062, TAK-227), leading pipeline presence.

Pfizer: Holds ~8–10% of global pipeline share via immunology and GI assets.

Investment Analysis and Opportunities

Over 25 biotech and pharma firms are engaged in pipeline development as of 2025. Takeda is advancing three late-stage assets. Licensing deals between small biotech and large pharma are increasing; 2–3 enzyme projects were licensed between 2023–2025. Biomarker development is a major investment theme, with patient registries being funded in the U.S. and EU. In emerging regions, investments are aimed at screening programs and diagnostic pathways, enabling trial readiness. Biologics manufacturing scale-up (e.g., IL-15 inhibitors, nanoparticles) requires USD 50–100M+ investment per facility. Venture funding is rising; at least 5 startups raised financing between 2023–2025 for enzyme and barrier therapies.

New Product Development

New product development in the celiac disease drug space is accelerating, with multiple novel mechanisms being pursued. In 2025, ZED1227, a transglutaminase 2 (TG2) inhibitor, remains a leading small-molecule candidate undergoing evaluation in mucosal healing trials. Wikipedia Takeda’s TAK-101 (tolerizing nanoparticle) is in Phase II development as an immunotherapy directed at antigen-specific tolerance.  Its oral enzyme candidate TAK-062 (zamaglutenase) has completed Phase II in November 2024.  Larazotide acetate is entering Phase III trials as a tight-junction modulator. Other enzyme therapies such as IMGX-003 / latiglutenase continue preclinical/early clinical assessment.

Five Recent Developments

• 2024 – Takeda completed Phase II for TAK-062 (enzyme therapy).
• 2025 – ZED1227 progressed in mucosal healing trials as a leading TG2 inhibitor.
• 2024 – Larazotide acetate entered Phase III as the first adjunct barrier modulator.
• 2024 – Ordesekimab (IL-15 inhibitor) advanced to Phase II in refractory disease.
• 2025 – Over 25 companies globally confirmed active clinical programs.

Report Coverage of Celiac Disease Drug Market

The Celiac Disease Drug Market Report covers mechanism segmentation (enzymes, TG2 inhibitors, immune therapies, barrier agents), clinical stage segmentation (preclinical to Phase III), and regional pipeline distribution. It highlights drivers (prevalence, unmet need), restraints (regulatory hurdles), and opportunities (adjunct therapies, RCD treatment). It quantifies pipeline size (25+ candidates) and regional trial activity (North America ~40%, Europe ~30%, Asia-Pacific ~20%, MEA ~10%). The report benchmarks leading firms (Takeda, Pfizer, Sanofi, BiolineRx) and provides insights into biomarker development, reimbursement risks, and launch strategies. Forecasts extend into 2030, modeling different approval and adoption timelines. 

Celiac Disease Drug Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1259.18 Million in 2026
Market Size Value By	USD 4107.66 Million by 2035
Growth Rate	CAGR of 14.04% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Distension Diarrhea Anorexia Others By Application : First Line of Treatment Second Line of Treatment
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample